MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma. - Wikidata - wikimedia - TriplyDB

MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.

MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.

http://www.wikidata.org/entity/Q33635350

about

Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy.Non-Viral Based miR Delivery and Recent Developments.The ASH1-miR-375-YWHAZ Signaling Axis Regulates Tumor Properties in Hepatocellular Carcinoma.Aptamers: novelty tools for cancer biology.Biodegradable Alginate-Chitosan Hollow Nanospheres for Codelivery of Doxorubicin and Paclitaxel for the Effect of Human Lung Cancer A549 Cells.Luteoloside Inhibits Proliferation and Promotes Intrinsic and Extrinsic Pathway-Mediated Apoptosis Involving MAPK and mTOR Signaling Pathways in Human Cervical Cancer Cells.MicroRNA-375 Suppresses the Tumor Aggressive Phenotypes of Clear Cell Renal Cell Carcinomas through Regulating YWHAZ Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin

P2860

Q47150956-EF5CA682-9653-4650-9E4B-AE29D273E192 Q54231141-65E3B864-0403-498B-B80A-902C5E64B422 Q55176168-31E6191C-9DD0-4EBC-A75B-09BC76B21122 Q55285633-D67657AA-B083-4D0F-92E6-40D62537FC4E Q55425710-94FFCC85-36B3-416F-97BB-7153A114E652 Q55669681-BA469C47-F279-40D7-B8E4-E1E0D9E007E0 Q58765846-76EAC845-6421-409D-BEFE-9BE3C3887E4A Q58777605-D2FEF216-03C7-485A-86EF-8ED92914D0C5 Q58795137-1F872869-5377-4CF8-99C0-B6EB72B6C95C

P2860

MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.

http://www.wikidata.org/entity/Q33635350

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

MiR-375 and Doxorubicin Co-del ...... y of Hepatocellular Carcinoma.

@ast

MiR-375 and Doxorubicin Co-del ...... y of Hepatocellular Carcinoma.

@en

type

label

MiR-375 and Doxorubicin Co-del ...... y of Hepatocellular Carcinoma.

@ast

MiR-375 and Doxorubicin Co-del ...... y of Hepatocellular Carcinoma.

@en

prefLabel

MiR-375 and Doxorubicin Co-del ...... y of Hepatocellular Carcinoma.

@ast

MiR-375 and Doxorubicin Co-del ...... y of Hepatocellular Carcinoma.

@en

P1433

Q33635350-E75A8179-1B3A-41FE-82B8-E156EF44BE56

P1476

Q33635350-D38A4523-A165-4021-A93A-FFAC484C8A45

P2093

Q33635350-23F19714-0734-4A62-8825-0A36DBDCC667

Q33635350-361FB4FA-3451-44FC-BFA7-F77CB182DC82

Q33635350-678282A8-1C0D-468E-971D-76281D0C5DDE

Q33635350-6A17F192-AA36-4AE8-B039-47DD1C427FE1

Q33635350-8F04AF4B-09B9-46F2-A056-8011D6E71CB7

Q33635350-B171D0EE-D13D-447A-8326-00F64468D64F

Q33635350-CCFC0B29-E406-4ADA-A803-D54FEEEA2AEE

Q33635350-D07AE58F-DFEE-4420-BAE7-2469CBDB7697

Q33635350-F9E474A6-8C08-4948-B0E4-953238D70653

P2860

Q33635350-1538614B-D896-4F72-A683-B345BDC2FBFE

Q33635350-17551BA4-8FBF-410C-82ED-3D53A0A95F5F

Q33635350-207B8E8C-5694-467D-9C3F-F583CCBF568D

Q33635350-220F9EC7-1218-48D8-9C27-E037CC79327C

Q33635350-27ADA85C-9ECB-4E4C-8F03-D7638705A7CA

Q33635350-2E0A32A4-6371-4C27-9634-94FD342A0039

Q33635350-3E815A8F-D515-4622-A138-565157E57E1D

Q33635350-4E5FBCE2-1687-47B3-9A44-AE34B14F7580

Q33635350-5FA693FA-AD36-4E98-9A84-73DE784AC5C6

Q33635350-61C03EE1-335B-4359-AA7C-1D3B3755ECDD

P304

Q33635350-94C3D7EF-037E-4EFF-BDDE-4BD2DAE88899

P31

Q33635350-E54232E5-85E1-4869-8589-01B9AFB868EA

P356

Q33635350-D9DF987F-1534-4DA0-818F-6AE56B79D056

P478

Q33635350-DB864247-97C3-4275-95A7-BD99AFCC7A7F

P577

Q33635350-A754BE58-E599-4ED8-A6B5-9FEC3FBA8226

P698

Q33635350-6D5B67CA-C680-4271-BBE2-4AB3EFF42E24

P932

Q33635350-E244DA2F-B189-45B3-852E-7D665F57D41A

P356

J.OMTN.2017.03.010

P1433

Molecular therapy. Nucleic acids

P1476

MiR-375 and Doxorubicin Co-del ...... y of Hepatocellular Carcinoma.

@en

P2093

De-An Tian

http://www.w3.org/2001/XMLSchema#string

Feng Ye

http://www.w3.org/2001/XMLSchema#string

Guang-Ya Xiang

http://www.w3.org/2001/XMLSchema#string

Jia-Zhi Liao

http://www.w3.org/2001/XMLSchema#string

Peng-Xuan Zhao

http://www.w3.org/2001/XMLSchema#string

Wang-Xian Tang

http://www.w3.org/2001/XMLSchema#string

Xing-Xing He

http://www.w3.org/2001/XMLSchema#string

Ya-Qi Lu

http://www.w3.org/2001/XMLSchema#string

Yin-Ping Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential

Global cancer statistics, 2012

Recent advances with liposomes as pharmaceutical carriers

Molecular mechanism of chemoresistance by astrocyte elevated gene-1.

MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.

Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Emerging role of microRNA in hepatocellular carcinoma (Review)

Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer

P304

181-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OMTN.2017.03.010

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28624193

http://www.w3.org/2001/XMLSchema#string

P932

5415965

http://www.w3.org/2001/XMLSchema#string